#ANGPTL3 it may be time for #ArrowheadTherapeutics and #VerveTherapeutics to reposition their ANGPTL3-targeting agents from currently only homoFH and potentially ASCVD...to much larger #MASH opportunity.

See also #EliLilly's solbinsiran and Arrowhead's zodasiran ANGPTL3 results:

#RNAi platform bios #SilenceTherapeutics and #ArrowheadTherapeutics thriving recently. Guess the recent deal flurry in sector is helping.

Hope that #Silence has been progressing #inhibinE for obesity as well. That, in addition to p3-ready Lpa, will clinch the deal.